We caution that this news release is not
making any express or implied claims that we have the ability to
eliminate the SARS-CoV-2 virus at this time. We
further caution that we have not undertaken any clinical
trials.
VICTORIA, April 17, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is
pleased to provide an update on its research activities for
the novel coronavirus (SARS-CoV-2) which outlines the Company's
workflows for their experimental vaccines and therapeutics for the
research community.
IPA's multitargeting approach combines various SARS-CoV-2 spike
protein forms with the Company's diverse technologies. Hence, IPA
anticipates that it can accelerate anti-SARS-CoV-2 human antibody
discovery, targeting multiple viral epitopes and mechanisms of
viral evasion, by immunizing Ligand's (NASDAQ:LGND)
OmniRat® animals using the Company's Rapid
Prime™ protocol followed by IPA's B cell
Select™ and hybridoma generation in parallel with
human, naive phage library screening. Subsequent high-throughput
binding assays, computational Artemis™ optimization, and
protein interaction analyses permit faster preclinical lead
selection.
"In addition to using our antibody discovery platforms
for the potentially rapid identification of a diverse
panel of fully SARS-CoV-2-specific antibodies, we aim targeting
additional novel epitopes which are likely inaccessible to
conventional antibody formats by screening our in-house, highly
complex, VHH repertoire (collection of variable regions of
heavy chain antibodies, a region which binds to the target
immunogen)," stated Ilse Roodink, Chairwoman
of Talem's Scientific Advisory Committee and Coronavirus
Global Project Leader. "Due to the relative high sequence
homology of VHHs with human antibodies, extensive humanization is
not required and therefore, our discovery strategy mixture will
significantly contribute to the fast generation of a monoclonal
antibody cocktail with broad epitope coverage and diverse
functionalities, which is key to successful development of an
effective, long-lasting therapy with a high safety profile."
Apart from the various SARS-CoV-2 spike protein forms which IPA
has been producing for use in the therapeutic development, data
obtained during the discovery and characterization of lead antibody
candidates may be of significant value in the reverse-engineering
of vaccine candidates used in the formulation of an effective, but
low-risk, vaccine.
Jennifer Bath, Ph. D., has
reviewed and approved the scientific disclosure contained in this
news release.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
Contract Research Organization offering species agnostic,
multi-format, characterized and engineered, human monoclonal
antibodies, on an abbreviated timeframe, for its pharmaceutical
clients. For further information, visit www.immunoprecise.com or
contact solutions@immunoprecise.com. There is no assurance that
ImmunoPrecise will be successful in the development of a vaccine
and/or therapeutic against the new coronavirus.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the last quarter of the fiscal year
ended January 31, 2020 which can be
accessed at www.sedar.com. The "forward-looking
statements" contained herein speak only as of the date of this
press release and, unless required by applicable law, ImmunoPrecise
undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-provides-updates-on-b-cell-select-and-deep-display-programs-for-sars-cov-2-antibody-discovery-301042543.html
SOURCE ImmunoPrecise Antibodies Ltd.